$Lexaria Bioscience (LEXX.US)$ most of sale on march 18 was short, let see how they cover...

$Lexaria Bioscience (LEXX.US)$ show me the cash!!

$Lexaria Bioscience (LEXX.US)$ at this sp we gonna be all shares target...

$Lexaria Bioscience (LEXX.US)$ each time wanna fly someone is stoping the trend...so frustrating...imho should be at +$3. but looks. im all wrong.

$Lexaria Bioscience (LEXX.US)$ $2.8/3 could b before year ends?

next $Lexaria Bioscience (LEXX.US)$

$Lexaria Bioscience (LEXX.US)$
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Thursday, 19th December at 9:05 am
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss
KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). Th...

$Lexaria Bioscience (LEXX.US)$ looks like someone w deep pockets is shorting our play....sad.

$Lexaria Bioscience (LEXX.US)$
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

$Lexaria Bioscience (LEXX.US)$
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Lexaria Bioscience provides a strategic update on the expanding therapeutic benefits of GLP-1 drugs, highlighting their growing applications beyond diabetes and weight loss. The market, dominated by semaglutide and tirzepatide, has seen remarkable growth from $300 million in 2018 to projected $30 billion in 2024. New therapeutic applications being investigated include he...